Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin vs Endocrine Therapy in HR+/HER2-low Metastatic Breast Cancer
NCT05904964Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2023
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Jul 2023; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05904964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904964.